Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

NCT00549744 | Completed Phase 2

• 1 other identifier: IPA107948
• Study Type: interventional
• Target: 78
• Locations: 2 countries
• Sites: 3

Brief Summary

Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days. Subjects will participate in 3 treatment periods.

Conditions

Asthma

Keywords

ASTHMA; CLINICAL ENDPOINT,

Outcome Measures

Primary Outcomes (1)

• Change from Baseline (pre-bronchodilator and pre-dose) forced expiratory volume at 1 second (FEV1) on Day 14

  FEV1 is a lung function measure defined as the maximal amount of air that can be forcefully exhaled in one second. Mean FEV1 from the 3 acceptable spirometric efforts were recorded after withholding salbutamol used as bronchodilator at all visits for at least 6 hours (h) and at pre-dose. Baseline was defined as the mean of the 3 pre-dose measurements on Day 1 of each treatment period. The change from Baseline was calculated by subtracting the Baseline value (Day 1, pre-dose) from the individual post-Baseline (pre-dose, Day 14) value. Adjusted mean was reported as least square (LS) mean.

  Baseline (Day 1, pre-dose) and Day 14 of each treatment period

Secondary Outcomes (26)

• Change from Baseline (pre-bronchodilator and pre-dose) FEV1 on Day 7 and at one h post-dose on Day 7 and Day 14

  Day 1 (Baseline, pre-dose), Day 7 and Day 14 of each treatment period

• Change from Baseline in FEV1 over 12 h post-dose on Day 1

  Baseline (Day 1, pre-dose) and Day 1 (0.5 h, 1 h, 2 h, 8 h and 12 h post-dose) of each treatment period

• Change from Baseline in FEV1 over 12 h post-dose on Day 14

  Baseline (Day 1, pre-dose) and Day 14 (0.5 h, 1 h, 2 h, 8 h and 12 h post-dose) of each treatment period

• Mean change from Baseline (pre-bronchodilator and pre-dose) Peak Expiratory Flow Rate (PEFR) averaged over the 14-day period

  Baseline (Screening, 7 days prior to Day 1 of Treatment period 1) and Day 1 to 14 of each treatment period

• Mean change from Baseline ratio of exhaled nitric oxide on Day 1, Day 7 and Day 14

  Baseline (Day 1 pre-dose), Day 7 and Day 14 of each treatment period

Interventions

GSK256066 DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with a screening pre-bronchodilator FEV1 70% predicted (having abstained from bronchodilators for the required period). Predicted values are based on the NHanes normal ranges
• During the screening visit, subjects must demonstrate the presence of reversible airway disease, defined as an increase in FEV1 of 12.0% over the max of the three screening measures and an absolute change of 150 mL within 30 minutes following a single 400 mg salbutamol dose
• Male and females who are aged between 18 and 65 years of age.A female is eligible to enter and participate in the study if she is of:
• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post menopausal. For the purposes of this study, post menopausal is defined as 1 year without menses (FSH/LH will be also tested to confirm menopausal status); or
• Child bearing potential, has a negative pregnancy test (urine) at screening and pre-dose Day 1, and agrees to one of the following acceptable contraceptive methods when used consistently and correctly (i.e., in accordance with the approved product label and the instructions of a physician for the duration of the study - screening visit to follow-up contact):
• Complete abstinence from intercourse from the screening visit, throughout the trial and for 7 (\~5 half-lives of GSK256066) days after the completion of the trial; or Male partner was sterile prior to the female subject's entry into the study, or Implants of levonorgestrel inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or Injectable progestogen administered for at least 1 month prior to the study medication administration and administered for 1 month following study completion; or Oral contraceptive (combined or progestogen only) administered for a least one monthly cycle prior to study medication administration; or The contraceptive transdermal patch, Ortho Evra (if the subject is less than 89kg); or Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm.
• Recent data now shows that certain double-barrier methods have a failure rate below 1% \[Trussell, 2003\]. Specifically, these are a spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm). This provides validated confirmation of the failure rate of the double-barrier method. Thus this method now meets the stated criterion for acceptable contraception in the EMEA guidelines \[CPMP/ICH/285/95, 2000\]; or Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or An intrauterine device (IUD) or intrauterine system (IUS), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; (not all IUDs meet this criterion) Acceptable IUDs: Tcu-380A (Paragard), TCU-380 Slimline (Gyne T Slimline), Tcu-220C, MULTILOAD-250 (MLCu-250) and 375, NOVA T and CUNOVAT (Novagard), Levonorgesterol (LNG-20) Intra-uterine System (Mirena/Levonova), and FlexiGard 330/CuFix PP330 (Gynefix). The device must be inserted at least 2 weeks prior to the Screen visit, and remain throughout the study and through the follow-up phase of the study or Any other methods with published data showing that the highest expected failure rate is less than 1% per year.
• Body weight of 50 kg and Body mass index within range of 19-31 kg/m2 inclusive
• Subjects who are current non-smokers, who have not used any inhaled tobacco products (snuff is permitted) in the 12 month period preceding the screening visit and who have a pack history of £ 10 pack years
• No significant abnormality on 12-lead ECG at screening, including the following requirements:
• Ventricular rate ≥ 40 beats per minute PR interval ≤ 200 ms Q waves \< 30 ms (up to 50 ms permitted in lead III only) QRS interval to be ≥ 60 ms and ≤ 110 ms QTc interval \< 450msec (QTcB or QTcF; machine or manual reading) based on a single ECG value, or an average from three ECGs obtained over a brief recording period
• Able to provide written informed consent
• The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions
• Demonstrated ability to use the inhaler device in a satisfactory and repeatable manner

You may not qualify if:

• As a result of medical interview, physical examination or screening investigations, the principle investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg unless the Investigator confirms that it is satisfactory for their age
• The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness
• Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease\*, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, bronchiectasis or pulmonary fibrosis)
• Subjects will require normal serum creatinine clearance values at screening \[calculated from serum creatinine by a predicting equation using Cockcroft-Gualt formula\]. If the creatinine clearance value is greater than the upper limit of normal as determined by the local laboratory reference range, the Investigator will determine whether this is a clinically significant finding that would preclude participation
• Subject has a history of atrial arrhythmia or ventricular arrhythmia
• Pregnant or nursing females
• Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception from at least two weeks prior to the first dose of study medication; and to continue until the final pregnancy test has been performed (not less than 150 hours after treatment
• Subjects with a history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with either respiratory arrest or hypoxic seizures
• Asthma exacerbations requiring treatment with oral corticosteroids: any exacerbations within 3 months of the screening visit or two or more exacerbations within 6 months of the screening visit or admittance to hospital for an asthma exacerbation within 1 year of the screening visit
• Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation
• Subjects who are unable to washout the following protocol defined prohibited medications within the defined times at screening:
• Oral corticosteroids Inhaled, intranasal and topical steroids Long acting beta agonists Short acting beta agonists
• The subject has taken prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety
• History of alcohol/drug abuse or dependence within 12 months of the study

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (3)

GSK Investigational Site

Wellington, 6035, New Zealand

Location

GSK Investigational Site

George, Eastern Cape, 6529, South Africa

Location

GSK Investigational Site

Bloemfontein, 9301, South Africa

Location

MeSH Terms

Conditions

Asthma

Interventions

6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 25, 2007
• First Posted: October 26, 2007
• Study Start: November 16, 2007
• Primary Completion: August 27, 2008
• Study Completion: August 27, 2008
• Last Updated: June 26, 2017

Record last verified: 2017-06

Locations

ZA (2); NZ (1)